Advanced Medical Solutions Group Plc · LSE:AMS
Advanced Medical Solutions — H1 2025 Earnings Presentation
24 slides from Advanced Medical Solutions's earnings presentation, Sep 17, 2025
Slide 1: Results for the six months ended 30 June 2025
Advanced Medical Solutions Results for the six months ended 30 June 2025 17 September 2025 1
Slide 2: Highlights – Strong performances throughout the enlarged Group
Highlights – Strong performances throughout the enlarged Group • 66% Group revenue growth driven by strong underlying momentum and acquisitions • 14% underlying revenue growth from AMS legacy business (excluding Peters) • Excellent performance from US and ROW LiquiBand® portfolio with 15% growth glo
Slide 3: Integrations progressing well, supporting synergies and performance
Integrations progressing well, supporting synergies and performance • Planning complete and execution phase progressing well • Implementation of commercial synergies positively influencing business: Peters Surgical integration • Direct revenue synergies targeting AMS products into Peters Cardiovascu
Slide 4: LiquiBand growth accelerating with strong global momentum
LiquiBand® growth accelerating with strong global momentum Strong US LiquiBand® growth supported by new ROW LiquiBand® revenues driven by strong end- marketing strategy user demand •Increased commitment from major US partners •Continued strong growth across multiple markets arising from new contract
Slide 5: Internal Fixation and Sealants, US end sales demand continues to build
Internal Fixation and Sealants, US end sales demand continues to build Hernia mesh fixation (branded LIQUIFIXTM in US and SEAL-G LiquiBand Fix8® OUS) • US end sales demand continues to build • Clinical data supportive of delivering real patient benefits – reduced severity of • Contracts in place wit
Slide 6: Sutures, Clips and VTO set for stronger H2
Sutures, Clips and VTO set for stronger H2 Surgical Sutures, Clips and VTO • RESORBA® Sutures - continue to deliver strong growth • End user demand remains robust across the portfolio • Peters Surgical revenues impacted by legacy supply issues and order phasing associated with US tariffs • Good prog
Slide 7: Biosurgical portfolio strengthened by Syntacoll
Biosurgical portfolio strengthened by Syntacoll Collagens Bone Substitute • Strong performance from collagen range • Freeze Dried Bone Substitute (FDBS) – • Syntacoll expertise significantly improving yields, resolving moldable and cohesive with capacity backorders experienced last year to mix with
Slide 8: Woundcare recovery on track, delivering margin expansion
Woundcare recovery on track, delivering margin expansion Restructuring program completed as planned at end of Q1 2025, including increased focused on higher margin business Delivering double-digit margins from Q2 2025 Strong recovery in revenue growth from refocused business: • Core Infection & Exud
Slide 9: New product launches and geographic expansion across the Group
New product launches and geographic expansion across the Group LiquiBand® and Resorba® IFABOND line SEAL-G® launch of second- Antibiotic collagen collagen launches Topical adhesives extension launches generation device approvals INDIA launch EU EU USA Advanced Closure/Biosurgical CHINA Internal Adhe
Slide 10: Financial Summary
Financial Summary a> Advanced Medical Solutions Group pic
Slide 11: Financial Highlights – Strong top-line growth, profitability and cashflow delivery
Financial Highlights – Strong top-line growth, profitability and cashflow delivery Revenue increased by 66% at constant currency to £110.8million and by 63% at reported currency Adjusted EBITDA increased 42% to £24.4 million Adjusted pre-tax profit increased 11% to £16.4 million Net debt of £50.1 mi
Slide 12: Revenue growth driven by expanded surgical portfolio
Revenue growth driven by expanded surgical portfolio Growth at H1 2024 H1 2025 • Group revenue up by 66%* to £110.8 million (H1 Division constant (£m) (£m) currency 2024: £68.0 million) • Surgical revenue up 86%* to £87.9 million (H1 AMS Surgical 48.4 53.6 +11% 2024: £48.4million) Peters Surgical -
Slide 13: LiquiBand and Fix8/LiquiFix
LiquiBand® and Fix8®/LiquiFixTM Advanced Closure £M Advanced Closure Internal Fixation and 25 £M Sealants • LiquiBand® revenue up 15%* to £24.5 million (H1 2024: £21.8 +15%* million) 5 • New US marketing strategy driving 18%* growth in the US 20 • Revenue includes an element of partner stock rebuild
Slide 14: Sutures, Biosurgical and Other – Expanded portfolio accelerates growth
Sutures, Biosurgical and Other – Expanded portfolio accelerates growth Sutures, Clips and VTO • Revenue up 283%* to £38.8 million (H1 2024: £10.4 million) Sutures, Clips and Other Distributed including Peters Surgical revenue not in prior period VTO Biosurgical products £M £M £M • Strong growth from
Slide 15: Woundcare – Revenue showing signs of recovery
Woundcare – Revenue showing signs of recovery Revenue up 18%* to £22.9 million (H1 2024: £19.5 million) £ M Infection & Exudate £M Other Woundcare Infection & Exudate Management Management 25 25 • Revenue up 26%* to £21.6 million (H1 2024: £17.2 million) with strong ordering from OEM partners 20 20
Slide 16: Surgical operating margins
Surgical operating margins Reflecting acquisitions ahead of synergy benefits and other margin accreting activities Surgical Surgical Business Unit £M • Adjusted operating margin 90.0 28% 30.0% decreased to 20% 80.0 25.0% 70.0 • Syntacoll initially around break- 20% 60.0 20.0% even but to be transfor
Slide 17: Woundcare operating margins
Woundcare operating margins Strengthening post-restructuring Woundcare Business Unit £M Woundcare 25.0 8% 9.0% 8.0% • Restructuring completed in Q1 2025 20.0 6% 7.0% • Focus on higher margin business 6.0% 15.0 • Recovery in revenue growth 5.0% 23 4.0% • Margins on track to reach double 10.0 20 3.0%
Slide 18: Exceptional Items and US Tariff Exposure
Exceptional Items and US Tariff Exposure Supporting integration, managed within guidance Exceptional items in H1 2025 Exceptional items 2025 H2 – of £3.0 million (H1 2024: £7.5 US Tariff Impact 2027 million) • Further integration costs are • Volumes impacted in H1 • Integration costs of £3 million:
Slide 19: Cashflow – Positioned for sustainable growth
Cashflow – Positioned for sustainable growth H1 2024 H1 2025 £ million (£m) (£m) Working Capital increase of £5.9 million Cash flows from operating activities: Profit from operations 3.9 10.7 • Inventory build supporting growth, resolve certain Depreciation and Amortisation 5.7 10.7 backorder situat
Slide 20: Environmental, Social and Governance
Environmental, Social and Governance The new group-wide sustainability team made good progress in the period: • Combining Net Zero reporting and carbon reduction planning for AMS and Peters Surgical • Implementing a unified ESG training and education program • Holding numerous events held such as Wo
Slide 21: Key Group Drivers 2025-2027 – Creating a surgical powerhouse
Key Group Drivers 2025-2027 – Creating a surgical powerhouse Robust organic revenue growth • Supported by strong end user demand, commercial synergies, geographic expansion and new product launches • Re-focused Woundcare business • Increased direct sales • Commercial synergies/cross-selling Improvin
Slide 22: Summary and Outlook
Summary and Outlook a> Advanced Medical Solutions Group pic
Slide 23: Summary & Outlook
Summary & Outlook Robust H1, integration on track, synergies driving growth • Strong financial performance in H1 2025 • LiquiBand® portfolio continues to perform well and drive growth • Biosurgical revenues boosted by Syntacoll integration • Woundcare re-structuring complete – cash generative busine
Slide 24: Contact
Contact Advanced Medical Solutions plc Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire W7 3RT, UK Chris Meredith (Chief Executive Officer) corporate@admedsol.com Eddie Johnson (Chief Financial Officer) +44 (0)1606 863500 Michael King (Investor Relations) www.admedsol.com 24
Advanced Medical Solutions — H1 2025 Earnings Presentation on 6ix